BACKGROUND: Approximately 30% of patients with thyroid nodules have indeterminate or suspicious fine-needle aspiration (FNA) biopsy results. Because their risk of cancer is approximately 20%, these patients undergo thyroidectomy. We hypothesized that genes that regulate cell-cycle progression would be differentially expressed in malignant versus benign thyroid nodules and could serve as diagnostic markers and markers of disease aggressiveness. METHODS: We used a cDNA array with 96 cell-cycle regulatory genes to identify differentially expressed genes in pooled benign versus malignant thyroid neoplasms. Genes up- or down-regulated by more than 2-fold in malignant thyroid neoplasms were further evaluated by real-time quantitative polymerase chain reaction (PCR) in 95 patients with hyperplastic nodules (n = 19), follicular adenoma (n = 19), follicular thyroid cancer (n = 19), the follicular variant of papillary thyroid cancer (n = 19), and papillary thyroid cancer (n = 19). RESULTS: cDNA array analysis showed that cyclin B1, MCM5, MCM7, RAD9, ubiquitin C, CDK6, SKP2, and APAF1 were up-regulated in malignant thyroid neoplasms. Real-time quantitative PCR showed that MCM5, MCM7, and RAD9 mRNA expression were significantly higher in malignant than in benign thyroid neoplasms (< or = 0.0012). The combined use of MCM5, MCM7, and RAD9 mRNA expression had a sensitivity of 98.2% and a specificity of 65.7%. The level of MCM7 mRNA expression was higher in T4 than in T1, T2, and T3 differentiated thyroid cancers (P < 0.0127). CONCLUSIONS: MCM5, MCM7, and RAD9 are overexpressed in malignant thyroid neoplasms of follicular cell origin. These genes may be useful markers of malignant thyroid neoplasms as an adjunct to FNA biopsy. MCM7 mRNA expression is higher in locally invasive differentiated thyroid cancer.
BACKGROUND: Approximately 30% of patients with thyroid nodules have indeterminate or suspicious fine-needle aspiration (FNA) biopsy results. Because their risk of cancer is approximately 20%, these patients undergo thyroidectomy. We hypothesized that genes that regulate cell-cycle progression would be differentially expressed in malignant versus benign thyroid nodules and could serve as diagnostic markers and markers of disease aggressiveness. METHODS: We used a cDNA array with 96 cell-cycle regulatory genes to identify differentially expressed genes in pooled benign versus malignant thyroid neoplasms. Genes up- or down-regulated by more than 2-fold in malignant thyroid neoplasms were further evaluated by real-time quantitative polymerase chain reaction (PCR) in 95 patients with hyperplastic nodules (n = 19), follicular adenoma (n = 19), follicular thyroid cancer (n = 19), the follicular variant of papillary thyroid cancer (n = 19), and papillary thyroid cancer (n = 19). RESULTS: cDNA array analysis showed that cyclin B1, MCM5, MCM7, RAD9, ubiquitin C, CDK6, SKP2, and APAF1 were up-regulated in malignant thyroid neoplasms. Real-time quantitative PCR showed that MCM5, MCM7, and RAD9 mRNA expression were significantly higher in malignant than in benign thyroid neoplasms (< or = 0.0012). The combined use of MCM5, MCM7, and RAD9 mRNA expression had a sensitivity of 98.2% and a specificity of 65.7%. The level of MCM7 mRNA expression was higher in T4 than in T1, T2, and T3 differentiated thyroid cancers (P < 0.0127). CONCLUSIONS:MCM5, MCM7, and RAD9 are overexpressed in malignant thyroid neoplasms of follicular cell origin. These genes may be useful markers of malignant thyroid neoplasms as an adjunct to FNA biopsy. MCM7 mRNA expression is higher in locally invasive differentiated thyroid cancer.
Authors: Kai Stoeber; Robert Swinn; A Toby Prevost; Pamela de Clive-Lowe; Ian Halsall; Stephen M Dilworth; Jackie Marr; William H Turner; Nigel Bullock; Andrew Doble; C Nicholas Hales; Gareth H Williams Journal: J Natl Cancer Inst Date: 2002-07-17 Impact factor: 13.506
Authors: E J Davidson; L S Morris; I S Scott; S M Rushbrook; K Bird; R A Laskey; G E Wilson; H C Kitchener; N Coleman; P L Stern Journal: Br J Cancer Date: 2003-01-27 Impact factor: 7.640
Authors: Howard B Lieberman; Joshua D Bernstock; Constantinos G Broustas; Kevin M Hopkins; Corinne Leloup; Aiping Zhu Journal: J Mol Cell Biol Date: 2011-02 Impact factor: 6.216
Authors: Menno R Vriens; Julie Weng; Insoo Suh; Nhung Huynh; Marlon A Guerrero; Wen T Shen; Quan-Yang Duh; Orlo H Clark; Electron Kebebew Journal: Cancer Date: 2011-10-17 Impact factor: 6.860
Authors: Xi-Yue Zhang; Lang-Zhu Tang; Bao-Guo Ren; Yan P Yu; Joel Nelson; George Michalopoulos; Jian-Hua Luo Journal: Am J Pathol Date: 2013-01-11 Impact factor: 4.307
Authors: Eva Weis; Holger Schoen; Anja Victor; Claudia Spix; Marco Ludwig; Brigitte Schneider-Raetzke; Nicolai Kohlschmidt; Oliver Bartsch; Aslihan Gerhold-Ay; Nils Boehm; Franz Grus; Thomas Haaf; Danuta Galetzka Journal: PLoS One Date: 2011-10-03 Impact factor: 3.240